Who is sponsoring NCT00537862?

NCT00537862 is sponsored by Novartis Pharmaceuticals.

What condition does NCT00537862 study?

NCT00537862 studies Kidney Transplant.

What drugs are being tested in NCT00537862?

Interventions: Enteric-Coated Mycophenolate Sodium (EC-MPS).

What is the status of NCT00537862?

NCT00537862 is currently COMPLETED.

Last reviewed 2017-02-22 · How we verify

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients ; A Prospective, Open Label, Multi-center Study

NCT00537862 Phase 4 COMPLETED

This study will evaluate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in a cyclosporine microemulsion based regimen with C2 monitoring in de novo kidney transplant recipients

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 4
Status	COMPLETED
Enrolment	200
Start date	2006-05

Conditions

Kidney Transplant

Interventions

Enteric-Coated Mycophenolate Sodium (EC-MPS)

Primary outcomes

Efficacy & safety of enteric-coated mycophenolate sodium combined with cyclosporine microemulsion & corticosteroids assessed by overall survival at 6 months, biopsy proven acute rejection, graft loss, adverse events and serious adverse events.

Countries

South Korea